Provided by Tiger Trade Technology Pte. Ltd.

Teva Pharmaceutical

33.99
+0.07500.22%
Volume:1.82M
Turnover:61.71M
Market Cap:39.59B
PE:28.09
High:34.22
Open:33.64
Low:33.52
Close:33.91
52wk High:37.35
52wk Low:12.47
Shares:1.17B
Float Shares:1.14B
Volume Ratio:0.28
T/O Rate:0.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.21
EPS(LYR):1.21
ROE:20.79%
ROA:6.17%
PB:5.01
PE(LYR):28.09

Loading ...

Has Teva (TEVA) Run Too Far After Its 102% One-Year Share Price Surge?

Simply Wall St.
·
Yesterday

FDA Accepts Teva's New Long-Acting Schizophrenia Treatment Application

Benzinga
·
Feb 23

Teva Pharmaceutical Says FDA Accepts New Drug Application for Olanzapine in Schizophrenia Treatment

MT Newswires Live
·
Feb 21

FDA accepts Teva NDA for olanzapine extended-release injectable suspension

TIPRANKS
·
Feb 21

BRIEF-Corcept Says US Court Rules Teva's Generic Korlym Does Not Infringe Corcept Patents

Reuters
·
Feb 20

Corcept Therapeutics Inc - Ruling Affirms December 2023 Verdict by Federal District Court

THOMSON REUTERS
·
Feb 20

Corcept Therapeutics Inc - Considering Judicial Review of Court Decision

THOMSON REUTERS
·
Feb 20

Corcept Provides Update on Patent Dispute With Teva Pharmaceuticals

THOMSON REUTERS
·
Feb 20

Truist Financial Sticks to Its Buy Rating for Teva Pharmaceutical (TEVA)

TIPRANKS
·
Feb 19

Teva Pharmaceuticals Is Maintained at Buy by Truist Securities

Dow Jones
·
Feb 18

BRIEF-Viking Global Reports Share Stake In Amazon, Raises In Boeing & T-Mobile, Dissolves In BlackRock

Reuters
·
Feb 18

Truist Securities Adjusts Teva Pharmaceutical Industries Price Target to $42 From $38, Maintains Buy Rating

MT Newswires Live
·
Feb 18

Teva Pharmaceutical's New Study Shows Lasting Relief For Inflammatory Bowel Disease Patients

Benzinga_recent_news
·
Feb 17

Teva and Sanofi’s duvakitug Phase 2b data shows efficacy in colitis and Crohn’s

TIPRANKS
·
Feb 17

BRIEF-Sanofi Says Phase 2B Study Shows duvakitug Efficacious In Ulcerative Colitis, Crohn's Disease

Reuters
·
Feb 17

Teva: Duvakitug Was Well Tolerated and Safety Was Consistent With Induction Study

THOMSON REUTERS
·
Feb 17

Teva and Sanofi’s Duvakitug Phase 2B Maintenance Data Demonstrated Clinically Meaningful Durable Efficacy in Ulcerative Colitis and Crohn’s Disease

THOMSON REUTERS
·
Feb 17

Teva (TEVA) Is Down 5.2% After Returning To Profitability On Innovation-Led Revenue Shift – What’s Changed

Simply Wall St.
·
Feb 12

Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Recent Share Price Momentum And Biosimilar Growth Hopes

Simply Wall St.
·
Feb 10

Teva Pharmaceuticals Is Maintained at Buy by Goldman Sachs

Dow Jones
·
Feb 10